US2003068276A1PendingUtilityA1

Dosage forms

Priority: Sep 17, 2001Filed: Nov 2, 2001Published: Apr 10, 2003
Est. expirySep 17, 2021(expired)· nominal 20-yr term from priority
A61K 9/2027A61K 9/5078A61P 25/30A61K 31/485A61K 9/4858A61K 9/2013A61K 45/06A61P 25/36A61K 9/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Solid oral dosage forms of controlled substances containing aversive agents are useful in reducing abuse by chewing or inhaling.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . An oral pharmaceutical dosage form not susceptible to abuse by respiratory mucosal membrane administration comprising one or more aversive agents.  
     
     
         2 . An oral pharmaceutical dosage form not susceptible to abuse by chewing comprising one or more aversive agents.  
     
     
         3 . An oral pharmaceutical dosage form not susceptible to abuse by respiratory mucosal membrane administration comprising one or more aversive agents and a controlled substance.  
     
     
         4 . An oral pharmaceutical dosage form not susceptible to abuse by chewing comprising one or more aversive agents and a controlled substance.  
     
     
         5 . An oral pharmaceutical dosage form according to  claim 3 , wherein said aversive agent is a respiratory irritant selected from the group consisting of capsaicin, capsacutin dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, capsaicinoids, gingerol, piperine, isopiperine, zingerone, shogaol, and vanyllylamide derivatives, and mixtures thereof.  
     
     
         6 . An oral pharmaceutical dosage form according to  claim 4 , wherein said aversive agent is a bitter substance selected from the group consisting of denatonium benzoate, denatonium capsaicinate, denatonium chloride, denatonium saccharide, limonin, linalool, linalool acetate, naringin, quassin, quercitin, sucrose benzoate, and sucrose octaacetate, and mixtures thereof.  
     
     
         7 . An oral pharmaceutical dosage form according to  claim 5 , wherein said controlled substance is selected from the group consisting of Schedule II, III, IV, and V controlled substances.  
     
     
         8 . An oral pharmaceutical dosage form according to  claim 6 , wherein said controlled substance is selected from the group consisting of Schedule II, III, IV, and V controlled substances.  
     
     
         9 . An oral pharmaceutical dosage form according to  claim 7 , wherein said controlled substance is a Schedule II controlled substance.  
     
     
         10 . An oral pharmaceutical dosage form according to  claim 8 , wherein said controlled substance is a Schedule II controlled substance.

Join the waitlist — get patent alerts

Track US2003068276A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.